Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
ASCENTAGE PHARMA GROUP INTERNATIONAL director David Sidransky has reported his initial equity holdings. He holds options linked to 56,550 Ordinary Shares with an exercise price of $8.14 per share, expiring on November 26, 2035. These stock options vest in four equal annual installments on each of November 26, 2026, 2027, 2028 and 2029.
He also holds 66,550 restricted stock units, each representing a right to receive one Ordinary Share upon vesting. These RSUs vest in four equal annual installments on each of November 26, 2026, 2027, 2028 and 2029 and have no expiration date. The filing does not show any open-market buying or selling activity, only existing awards.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Simon Dazhong Lu reports existing equity awards, not new trades. He holds stock options linked to 53,895 Ordinary Shares with an exercise price of 8.1400 per share, expiring on November 26, 2035, vesting in four equal parts from November 26, 2026 through 2029. He also holds restricted stock units covering 63,895 Ordinary Shares, vesting in the same four annual installments and with no expiration date.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Marc E. Lippman reports his equity holdings in the company. He holds 21,174 Ordinary Shares directly. He also holds options over 53,895 Ordinary Shares with an exercise price of $8.14 per share, based on conversion from HKD, expiring on November 26, 2035. These stock options vest in four equal annual installments on each of November 26, 2026, 2027, 2028 and 2029. In addition, he holds 63,895 restricted stock units, each representing one Ordinary Share, which vest on the same four annual dates and have no expiration date.
ASCENTAGE PHARMA GROUP INTERNATIONAL director Debra Yu filed an initial Form 3 showing equity awards in the company. She holds stock options linked to 53,895 Ordinary Shares with an exercise price of $8.14 per share, expiring on 11/26/2035, vesting in four equal annual increments from 11/26/2026 through 2029.
She also holds restricted stock units covering 63,895 Ordinary Shares. Each RSU represents the right to receive one Ordinary Share upon vesting. These RSUs vest in four equal annual installments on 11/26/2026, 2027, 2028 and 2029 and have no expiration date.
Ascentage Pharma Group International filed a Form 6-K detailing that four preclinical studies from its oncology pipeline have been selected for poster presentations at the AACR Annual Meeting 2026 in San Diego. The work covers three novel drug candidates: the BCR-ABL inhibitor Olverembatinib (HQP1351), the FAK/ALK/ROS1 inhibitor APG-2449, and the PRC2/EED inhibitor APG-5918 across endometrial carcinoma, mantle cell lymphoma, BRAF V600E-mutant tumors and small-cell lung cancer models.
The filing also highlights that Ascentage Pharma is a commercial-stage biopharmaceutical company with two approved products in China: Olverembatinib for multiple chronic myeloid leukemia indications and Lisaftoclax for CLL/SLL after prior systemic therapy including BTK inhibitors. Both lead assets are in multiple global registrational Phase III trials, underscoring an advanced late-stage pipeline.
Ascentage Pharma Group International has called a board meeting for March 25, 2026. At this meeting, the board plans to review and, if appropriate, approve the Group’s annual results for the year ended December 31, 2025 and consider declaring a final dividend. The notice also confirms the current composition of the board, including Chairman and Executive Director Dr. Yang Dajun and a mix of non-executive and independent non-executive directors.
Ascentage Pharma Group International will release its full year 2025 unaudited financial results and provide business updates on March 25, 2026 at 7:00 pm EDT / 7:00 am HKT. The company will host investor webcasts with Q&A in both Mandarin and English, led by management.
Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel cancer therapies, including its approved drugs Olverembatinib and Lisaftoclax. It is running multiple registrational Phase III trials and maintains partnerships with major pharma companies and leading research institutions.
Ascentage Pharma Group International filed a report noting that its management will participate in three upcoming investor conferences. The related presentations and fireside chats will be available via webcasts on the Events page in the Investor Relations section of the company’s website.
The filing also reiterates that Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel cancer therapies, including its approved products Olverembatinib for chronic myeloid leukemia and Lisaftoclax for certain blood cancers, alongside multiple global Phase III trials and collaborations with major pharmaceutical companies and leading research institutions.
Ascentage Pharma Group International furnished a report highlighting its upcoming participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. Company management will join a fireside chat at 9:30 a.m. EST on Thursday, February 12, with a live webcast available through the Events page of its investor relations website.
The filing also reiterates that Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel cancer therapies. Its lead drug Olverembatinib is approved in China for multiple chronic myeloid leukemia indications and covered by the China National Reimbursement Drug List. A second approved product, Lisaftoclax, treats certain chronic lymphocytic leukemia/small lymphocytic lymphoma patients and supports several global registrational Phase III trials in hematologic malignancies and myelodysplastic syndromes.
Ascentage Pharma Group International filed a Form 6-K to share that its BTK-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the China Center for Drug Evaluation (CDE). This follows a prior IND clearance from the U.S. Food and Drug Administration.
The company plans a multicenter, open-label Phase I trial in patients with relapsed or refractory hematologic malignancies to assess safety, tolerability, pharmacokinetics, and preliminary efficacy. APG-3288, built on Ascentage’s PROTAC technology, is designed to degrade both wild-type BTK and multiple resistance-associated BTK mutants, potentially addressing treatment-resistant B‑cell cancers and complementing its existing hematology portfolio, including Olverembatinib and Lisaftoclax in China.